The lack of female representation in clinical trials impairs the very foundation that the development of safe and effective medicines is built upon.

Care must be taken to ensure patients understand the difference between gene therapy and the different kinds of gene editing.

Efficient data management is critical to meet the demand for fast drug development – especially in light of COVID-19

Experts from the BIA got together to discuss how the UK’s biotechnology industry can plug the UK’s worrying skills gap.

Are there learnings from the COVID-19 pandemic that could be applied to the development and commercialization of advanced therapies?

Using CRISPR to engineer cell therapies with multiple gene knockouts could be limited by double-strand breaks.

Is there data demonstrating significant cost benefits from continuous biomanufacturing?

As trials change and adapt, so too must clinical packaging.

How do we choose the right bioprocessing technologies for the short and long term?

Could zinc finger therapy hold the key to treating Alzheimer’s disease?